Imran Alibhai, Ph.D.
Chief Executive Officer
Prior to becoming CEO of Tvardi, Imran Alibhai, Ph.D. was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotech company developing oncolytic viruses for cancer. Previously, Dr. Alibhai was an investment banker in PJ Solomon’s Healthcare Advisory Group, focused on M&A transactions in science-based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. Formerly, he was the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. He also directed investments for PIPE’s and long/short positions in MPM Capital’s BioEquities hedge fund. Dr. Alibhai began his career in early stage venture capital at the Accelerator Corp., where he was involved in every facet of company/project formation and management. He currently serves on the Scientific Advisory Board for NASA’s Translational Research Institute for Space Health. Dr. Alibhai holds a Ph.D. in Molecular Neuroscience from the University of Texas Southwestern Medical School and a BS in Biology from Duke University.
Jeno Gyuris, Ph.D.
Chief Scientific Officer and Chairman of Scientific Advisory Board
Jeno Gyuris Ph.D. brings 25 years of scientific leadership experience in the biopharmaceutical industry and a deep understanding of basic cancer research and translational biology as well as oncology drug discovery and development. A veteran of the Cambridge biotech cluster, Dr. Gyuris previously served as the Chief Scientific Officer of Trieza Therapeutics and has held a number of scientific leadership positions including Chief Scientific Officer of Aveo Pharmaceuticals and Executive VP, Research and Development and Chief Scientific Officer for Quiet Therapeutics. Dr. Gyuris received his Ph.D. from the University of Szeged, Hungary, and completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital.
Jeff Larson, Ph.D., DABT
Senior Vice President, R&D
Jeffrey Larson Ph.D., DABT is a board certified toxicologist with 25+ years of broad experience in drug development, primarily across nonclinical research, safety toxicology and clinical/nonclinical pharmacokinetics. His career has spanned a range of clinical therapeutic areas includes oncology, anti-viral, anti-fungal, anti-inflammatory, respiratory, dermatology and ophthalmic indications. Previously, Dr. Larson was the Vice President of Product Development for Iterion Therapeutics and held senior positions at Beta Cat Pharmaceuticals, and Salarius Pharmaceuticals. He has held a number of positions within the pharmaceutical industry, with increasing responsibilities and scope of activities including at Rhone-Poulenc Rorer (now Sanofi Aventis), Allergan, and Tanox. Dr. Larson earned a Ph.D. in Toxicology/Pharmacology from Washington State University and is a Diplomate of the American Board of Toxicology.
Sofia de Achaval, M.S., Ph.D.
Vice President, Development
Sofia de Achaval, M.S., Ph.D. oversees the chemistry, manufacturing and controls and clinical operations at Tvardi. She has 10+ years of experience in clinical research spanning multiple indications including oncology and inflammation. During her time at The University of Texas MD Anderson Cancer Center she has had integral roles establishing basic, translational, and clinical research collaborations within and outside of the institution. For those collaborations she was responsible for regulatory and compliance, clinical research, and data management teams. Dr. de Achaval led the development of the IND of TTI-101 in cancer and spearheaded the planning and initiation of the first-in-man Phase 1 studies. She holds Master of Science and Doctor of Philosophy degrees in public health – epidemiology from The University of Texas Health Science Center, School of Public Health and BS in Biology from Texas A&M University.
Ron DePinho, M.D.
Chairman of Board of Directors, Scientific Advisory Board Member, and Co-Founder
Ronald Depinho, M.D. has had a distinguished career in cancer research including his role as President of the University of Texas, MD Anderson Cancer Center. During his tenure as MD Anderson’s president, Dr. DePinho conceived and launched the Cancer Moon Shots Program, maintained MD Anderson’s top ranking, dramatically enhanced its research and training excellence, recruited many world class faculty, and expanded its global network to reach one-third of the human population. His research program has made fundamental contributions to our understanding and treatment of cancer, aging and degenerative disorders. He is a member of the National Academy of Science and National Academy of Medicine and recipient of honorary degrees and many awards including the Ellis Island Medal of Honor and knighthood from Portugal. Dr. DePinho has successfully founded and raised capital for numerous biotech companies including publicly traded Aveo and Karyopharm. He was an advisor for biotech firms, Epizyme and Agios as well as Abbott and GSK. He holds an M.D. from Albert Einstein College of Medicine and a B.S. from Fordham University.